Review Links PMOS and PCOS to Alzheimer's Disease and Dementia Risk

Evidence Links PMOS to Cognitive Changes and Dementia Risk

Women with polyendocrine metabolic ovarian syndrome (PMOS), formerly called polycystic ovary syndrome (PCOS), face a higher risk of developing Alzheimer's disease and dementia. A systematic review published in the Journal of the Endocrine Society examined PubMed records from inception through October 2025 to evaluate cognitive outcomes in patients with the condition.

PMOS affects 10% to 15% of women worldwide and can produce lifelong health complications. The syndrome is already associated with type 2 diabetes, cardiovascular disease, stroke, depression, anxiety, infertility, and endometrial cancer. The condition can also affect males, though clinical presentations differ by sex.

Metabolic Comorbidities Drive the Observed Association

Shared metabolic dysfunction appears to explain the statistical connection between PMOS and neurodegenerative disease. Co-author Ricardo Azziz of the University of Alabama at Birmingham stated that the association is likely mediated by metabolic comorbidities, specifically insulin resistance and obesity, rather than an independent direct effect of PMOS itself.

Insulin resistance disrupts normal glucose metabolism throughout peripheral tissues and the central nervous system. When chronic hyperinsulinemia and excess adiposity persist, both vascular health and cerebral metabolic pathways sustain measurable damage. Addressing these underlying metabolic drivers remains central to clinical management.

Measurable Changes in Memory and Brain Structure

Patients diagnosed with PMOS demonstrate subtle but documented shifts in cognitive performance well before midlife. Clinical evaluations show mild but reproducible deficits in executive function and memory recall.

Imaging studies cited in the review also identify structural and functional alterations in the brain. Researchers deduced that these neurological changes parallel biological pathways implicated in Alzheimer's disease progression, reinforcing the need for early metabolic intervention.

Gaps in Knowledge and Areas for Future Research

The published review synthesizes existing observational data but cannot confirm a direct causal link between PMOS and dementia. The authors noted that significant research gaps remain regarding how ovarian hormone fluctuations interact with systemic insulin resistance over decades.

Future clinical trials are required to determine whether treating insulin resistance early in reproductive-aged women lowers later dementia incidence. Individuals managing PMOS should discuss their long-term metabolic markers, including fasting insulin, blood glucose, and body mass index, with their healthcare team.